Second, recent studies have demonstrated modulation of FABP4 concentration by therapeutic drugs for hypertension, dyslipidemia and diabetes mellitus40–45,51,52, which might have affected cardiovascular events, though diagnosis of hypertension, dyslipidemia and diabetes mellitus was adjusted in Cox proportional hazard model analysis (Table 3, Model 4). Here, FABP4 is linked to metabolic syndrome.